Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244880 · ClinicalTrials.gov registry record · Phase 1
Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01244880 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 4 participants.
The verdict
NCT01244880, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
To evaluate whether PF-02545920 reduces the effects of ketamine on brain activation during causal learning as measured by fMRI compared to placebo in healthy human subjects, and to evaluate whether behavioral measures of abnormal causal learning under ketamine are reduced by treatment with PF 02545920.
Interventions
- OTHER Saline
- DRUG PF-02545920
- OTHER Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01244880
The ClinicalTrials.gov registry entry for NCT01244880 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT01244880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01244880 about?
NCT01244880 is a clinical study titled "Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects". To evaluate whether PF-02545920 reduces the effects of ketamine on brain activation during causal learning as measured by fMRI compared to placebo in healthy human subjects, and to evaluate whether behavioral measures of abnormal causal learning under ketamine are reduced by treatment with PF 025459...
What is the current status of trial NCT01244880?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2011-04. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01244880?
The interventions under investigation include: Saline (OTHER), PF-02545920 (DRUG), Ketamine (OTHER).
Who is sponsoring clinical trial NCT01244880?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.